Lyme disease: mystery, misery and hope
15 July 2016 | By Victoria White, Digital Content Producer
Drug Target Review recently caught up with Veronica Hughes, CEO of the Caudwell Lyme Disease charity, to find out more about the disease...
List view / Grid view
Articles
Translating stem cell biology into drug discovery
Pluripotent stem cell research has made extraordinary progress over the past decade. The robustness of nuclear reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) has created entirely novel opportunities for drug discovery and personalised regenerative medicine...
EU Referendum: Tell us what you think…
20 June 2016 | By Caroline Richards, Editor, Drug Target Review
As Britons go to polling stations to vote in the EU Referendum, we can't help but wonder how you feel...
Theravance on Vibativ and fighting antimicrobial resistance
20 June 2016 | By Victoria White, Digital Content Producer
We recently caught up with Frank Pasqualone of Theravance Biopharma to find out about the latest study results for the company's antibiotic, Vibativ...
The next revolution in stratified medicine: molecular phenotyping with metabolomics
The study of biochemistry provides molecular insights into how the human population ages, how diseases commence and progress, how molecular changes relate to disease remission and relapse, and how humans respond to treatments...
Modulating the microbiome
17 June 2016 | By Caroline Richards, Editor, Drug Target Review
While the negative effects of microorganisms that invade the body are clear, and particularly now we are facing a worrying future without effective antibiotics, the potential for our own colonies of bacteria to improve our health has recently been subjected to much promising research...
Drug Target Review – Issue #2 2016
16 June 2016 | By Drug Target Review
Included in this issue: Mass Spectrometry, Rare Diseases, Omics, Kinases, Stem Cells, Label-Free and much more...
Omics In-Depth Focus 2016
Featured in this Omics In-depth Focus: The next revolution in stratified medicine-molecular phenotyping with metabolomics; Pharmacometabolomics as the key to personalised medicine...
Stem Cells In-Depth Focus 2016
Featured in this Stem Cells In-depth Focus: Translating stem cell biology into drug discovery; Mechanism-informed phenotypic screening – the missing link for cancer drug discovery; Analysis of human stem cell interactions at the single-cell resolution...
Organs-on-chips gearing up to disrupt the microbiome market
The human microbiome, comprising of the complex and dynamic microbial communities found on the human body, is essential to our health and observed differences in its composition between patients and healthy people have lead to speculations about the involvement of bacteria in disease development. Such differences have provided evidence towards…
Advanced techniques and applications of LC-MS in small molecule drug discovery
A key process in drug discovery is the ability to identify new drug candidates by screening chemical libraries of small molecules, natural products or extracts against a biological target and selecting lead compounds with desirable therapeutic effects. Medicinal chemistry has the challenging role of not only ensuring that the chemical…
Rare Diseases Q&A
Releasing colourful balloons into the air to symbolise people who are affected by rare diseases was one of the many ways in which this year’s Rare Disease Day was marked in February. The once-yearly, global campaign aims to raise awareness among the general public and decision-makers about these illnesses and…
Inhibition of RNA-containing viruses by artificial RNases
The toxicity and antiviral properties of 24 low-molecular-weight artificial RNases (artRNases) including peptides, peptidomimetics, N-alkyl-substituted 1,4-diazabicyclo[2.2.2]octane (DABCO) and a silver (I) complex with cystine were analysed for viruses containing single-stranded and double-stranded genomic RNA (the tick-borne encephalitis virus; TBEV and the influenza virus, respectively) in vitro and in vivo by…
New horizons in next-generation small molecule kinase inhibitors
In the pre-imatinib (Glivec®) era, two out of three patients died within five years from chronic myeloid leukemia and there was no hope for a curative treatment. Imatinib’s introduction in 2001 marked a breakthrough – as the first approved kinase inhibitor, it was a game-changer in cancer therapy and revolutionised…
Pharmacometabolomics as the key to personalised medicine
Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...
